SOUTH SAN FRANCISCO, Calif.,
May 28, 2015 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Jefferies 2015 Global Healthcare Conference
in New York City on Wednesday, June 3rd at 1:30 p.m. ET.
To access the live audio webcast or the subsequent archived
recording, log on to www.rigel.com. Please connect to Rigel's
website several minutes prior to the start of the live webcast to
ensure adequate time for any software download that may be
necessary.
About Rigel
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology
company focused on the discovery and development of novel,
small-molecule drugs for the treatment of inflammatory diseases,
autoimmune diseases, and cancers. Rigel's pioneering research
focuses on signaling pathways that are critical to disease
mechanisms. Rigel currently has the following product candidates in
development: fostamatinib, an oral spleen tyrosine kinase (SYK)
inhibitor, which is in Phase 3 clinical trials for ITP and
initiating a Phase 2 clinical trial for IgA nephropathy (IgAN);
R348, an ophthalmic JAK/SYK inhibitor, in a Phase 2 clinical trial
for dry eye in ocular graft-versus-host disease (GvHD); two
oncology product candidates in Phase 1 development with partners
BerGenBio AG and Daiichi Sankyo; and two preclinical programs with
partners AstraZeneca, for R256 in asthma, and Bristol-Myers Squibb,
for TGF beta inhibitors in immuno-oncology.
Contact: Ryan D. Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2015-global-healthcare-conference-300089995.html
SOURCE Rigel Pharmaceuticals, Inc.